![]() |
| Close Window |
| Media Information - 16/07/01 |
| Scottish Scientist leads team in development of Anthrax Vaccine |
Scottish scientist, Sir William Stewart, has led a team responsible for developing an anthrax vaccine in the only laboratory anywhere in the world which is able to manufacture a licensed vaccine against Anthrax. The Centre for Applied Microbiology & Research (CAMR), which is a Special Health Authority responsible to the Department of Health, based at Porton Down, is to supply the vaccine to the Ministry of Defence. The strategic importance of the anthrax vaccine to the UK was highlighted during the Gulf conflict when it was feared that Iraq would use biological weapons against Allied forces. The development of weapons containing anthrax has led to a threat ofinfection by the aerosol route, resulting in the vaccination being offered to service personnel who may be exposed to such a risk. This announcement is the culmination of over two years intensive work by staff at the Centre, which has seen the vaccine production unit rebuilt and refurbished at a cost of over £2 million. The result is a state of the art facility which meets all the requirements of a modern pharmaceutical plant. Sir William Stewart, President of The Royal Society of Edinburgh & Chairman of the Microbiological Research Authority said:
CAMR is the operating laboratory for The Microbiological Research Authority and is a distinct organisation from the Chemical and Biological Defence sector of DSTL Porton Down, which is responsible to the Ministry of Defence. For More information contact Information about Anthrax What is Anthrax ? Who gets Anthrax? How is Anthrax transmitted? What are the symptoms of Anthrax? Cutaneous: Most anthrax infections occur when the bacteria or its spores enter a cut or abrasion on the skin, such as when handling contaminated wool, hides, leather or hair products of infected animals. Skin infection begins as a raised itchy bump that resembles an insect bite but within 1-2 days develops into a vesicle and then a painless ulcer, usually 1-3 cm in diameter, with a characteristic black necrotic (dying) area in the centre. Lymph glands in the adjacent area may swell. About 20% of untreated cases of cutaneous anthrax will result in death. Deaths are rare with appropriate antimicrobial therapy. Intestinal: The intestinal form of the disease may follow the consumption of contaminated meat and is characterised by an acute inflammation of the intestinal tract. Initial signs of nausea, loss of appetite, vomiting, fever are followed by abdominal pain, vomiting of blood, and severe diarrhoea. Intestinal anthrax results in death in 25% to 60% of cases. Pulmonary: A large number of spores (approx 10,000 +) need to be inhaled in order for pulmonary anthrax to occur. Onset of symptoms would be expected to occur within a couple of days post exposure and would initially include mild fever. Within several days the symptoms progress to severe difficulty in breathing and toxic shock. Fatality estimates of 80-90% have been suggested. How soon after infection do symptoms appear? When and for how long is a person able to spread anthrax? What is the treatment for anthrax? How many cases of Anthrax occur in the UK ? What vaccines are available ? Does the Anthrax Vaccine have any side effects ? |
| For Media Enquiries, please contact: Stuart Brown Public Relations Officer, The Royal Society of Edinburgh, 22-26 George Street, Edinburgh, EH2 2PQ Tel : +44 (0)131 240 5000 Mobile : 077 11 710 249 Fax +44 (0)131 240 5024 |